Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
10,079 total articles
NVIDIA introduced Cosmos 3, the world's first fully open omnimodel for physical AI that integrates vision reasoning, multimodal generation, and action prediction to advance robotics, autonomous vehicles, and physical AI applications. The company also announced the formation of the NVIDIA Cosmos Coalition, partnering with leading AI labs and robotic…
NVIDIA announced the DGX Station for Windows, a powerful deskside AI supercomputer designed to run frontier AI models of up to 1 trillion parameters locally on Windows systems. Built on the NVIDIA GB300 Grace Blackwell Ultra Desktop Superchip, the DGX Station bridges the gap between high-end Linux data center AI workloads and the Windows productivi…
NVIDIA and Microsoft unveiled the NVIDIA RTX Spark, a powerful AI-focused superchip designed to transform Windows PCs into AI-native personal agent devices, combining high AI compute performance with robust security features and broad support from major PC makers and software providers. The RTX Spark platform promises significant advances in gaming…
NVIDIA announced the release of its new AI Agent Toolkit, featuring NemoClaw blueprints, Nemotron open models, OpenShell secure runtime, and CUDA-X libraries to facilitate development of autonomous AI agents for enterprises. Key industry leaders like Cadence, Dassault Systèmes, Siemens, and Synopsys are employing these tools to accelerate engineeri…
NIO Inc. announced a 62.3% year-over-year increase in May 2026 vehicle deliveries, totaling 37,705 units, including strong sales across its NIO, ONVO, and FIREFLY brands. The company launched the ONVO L80 and the flagship ES9 SUV in May, both receiving positive market feedback, solidifying NIO's leadership in the premium smart electric vehicle segm…
NVIDIA unveiled Vera, a high-performance CPU optimized for agentic AI and diverse data center workloads. Vera promises 1.8x faster task completion compared to x86 CPUs and is supported by major AI labs, hyperscalers, and system manufacturers. It is built to power AI infrastructure from standalone servers to integrated platforms, delivering improved…
NVIDIA announced the Vera BlueField-4 STX platform featuring enhanced DOCA security capabilities that provide zero-trust file access, agent behavior visibility, and network isolation to support secure agentic AI storage. This technology enables significantly faster runtime threat detection and policy enforcement at high network speeds, catering to …
NVIDIA announced that its Vera Rubin AI platform is ramping into full production, with major server manufacturers and ecosystem partners globally building systems at scale. Designed as a POD-scale platform, Vera Rubin delivers 10x agent throughput over previous generations, integrates cutting-edge technologies including Spectrum-X Ethernet Photonic…
NVIDIA introduced the DSX platform, an end-to-end solution enabling infrastructure builders to design, deploy, and operate AI factories efficiently. The platform includes new open source software for maximizing token performance per megawatt and managing AI factory operations, combined with validated hardware reference designs and simulation tools,…
BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in immuno-oncology, announced the pricing of a best-efforts offering of approximately 1.45 million common shares at $3.25 per share, expecting gross proceeds around $4.7 million. The offering aims to support working capital, general corporate purposes, and advancement …
Ascentage Pharma announced positive clinical data from a Phase Ib study combining its core drug olverembatinib with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) and Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL). The combination showed high response rates and man…
Ascentage Pharma presented the first clinical dataset for its MDM2-p53 inhibitor alrizomadlin (APG-115) used alone or with lisaftoclax in pediatric relapsed or metastatic rhabdomyosarcoma and other soft-tissue sarcomas. The data demonstrated preliminary antitumor activity, including complete and partial responses, and a manageable safety profile in…
Ascentage Pharma shared updated clinical results for olverembatinib, a third-generation BCR-ABL1 inhibitor, showing high efficacy and manageable safety as a second-line therapy for chronic-phase chronic myeloid leukemia patients at the 2026 ASCO Annual Meeting. The data demonstrated progressively deepening responses over 24 treatment cycles, suppor…
Diana Shipping Inc., the largest shareholder in Genco Shipping & Trading, has sent an open letter advocating for the election of six new independent directors to Genco's board, criticizing the current board's governance and management compensation practices. Diana has increased its all-cash tender offer to $24.80 per share, representing a 39% premi…
urban-gro, Inc. (Nasdaq: UGRO) announced the player auction for Season 6 of the Lanka Premier League scheduled on June 1, 2026, ahead of the July-August tournament. Through its subsidiary Innovative Production Group FZ, LLC, urban-gro is involved in the LPL's media, sponsorship, and activation activities but does not own or operate the league. The …
Immatics N.V. presented extended Phase 1 data for its TCR bispecific candidate IMA401 targeting MAGEA4/8 in heavily pretreated solid tumor patients, showing favorable tolerability and encouraging anti-tumor activity across multiple indications including head and neck cancer, melanoma, and lung cancer. The data supports combining IMA401 with IMA402 …
Revolution Medicines announced positive topline results from its pivotal Phase 3 RASolute 302 trial showing daraxonrasib significantly improves overall survival and progression-free survival compared to chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The trial met all primary and key secondary endpoints with a…
Immunocore Holdings plc reported updated Phase 1/2 data for brenetafusp monotherapy in heavily pretreated HLA-A*02:01-positive advanced melanoma patients, achieving a 6-month overall survival rate of 87% and disease control rate of 52%. The data support selecting a 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced mela…
Replimune Group, Inc. presented final first-in-human Phase 1 data for its investigational oncolytic immunotherapy RP2, both as monotherapy and in combination with nivolumab, in heavily pretreated patients with advanced solid tumors. The therapy showed an objective response rate around 19%, durable responses, and evidence of systemic immune activati…
Eikon Therapeutics announced encouraging clinical trial data for its lead candidates EIK1001 and EIK1003 at ASCO 2026. The Phase 2 TeLuRide-005 trial of EIK1001 in combination with standard therapies for first-line stage 4 NSCLC showed high response and disease control rates with manageable safety. Updated Phase 1/2 data for EIK1003, a selective PA…
BioNTech and Bristol Myers Squibb announced encouraging interim Phase 2 results from the global ROSETTA Lung-02 trial evaluating pumitamig, a PD-L1xVEGF-A bispecific immunomodulator, combined with chemotherapy in treatment-naive advanced non-small cell lung cancer (NSCLC) patients. The therapy demonstrated robust objective response rates across NSC…
Mineralys Therapeutics presented new positive clinical data from its Phase 3 Launch-HTN trial showing that lorundrostat, a highly selective aldosterone synthase inhibitor, significantly lowered systolic blood pressure and reduced albuminuria in patients with hypertension and chronic kidney disease (CKD). The drug demonstrated a favorable safety pro…
Cogent Biosciences announced highly positive results from the PEAK Phase 3 trial demonstrating that the combination of bezuclastinib and sunitinib significantly improves progression-free survival and response rates in gastrointestinal stromal tumor (GIST) patients resistant to imatinib. The combination showed a median progression-free survival of 1…
Molecular Partners AG announced presentations at the 2026 ASCO and SNMMI meetings showcasing trial-in-progress data from their Phase 1/2a study of MP0712, a targeted alpha radiotherapy candidate for small cell lung cancer and neuroendocrine tumors. MP0712 uses a novel Radio-DARPin platform targeting DLL3, a protein highly expressed in tumors but lo…
Replimune Group, Inc. announced positive 3-year overall survival results from the IGNYTE clinical trial evaluating its lead product candidate RP1 in combination with nivolumab in patients with anti-PD-1 failed advanced melanoma. Nearly half of treated patients were alive at three years, with 83.5% survival among responders, demonstrating durable be…
